Read on to learn about what to eat when prescribed semaglutide
70 Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al
Clinical trial data for semaglutide has documented this risk
Published in JAMA Neurology, the study highlights the potential of GLP-1 RA therapy as an alternative approach to managing this challenging neurological condition
It suggests they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight or obesity with cardiovascular disease, or CKD. Drug could help the one in 10 people with chronic kidney disease Originally developed to treat diabetes, GLP-1 receptor agonists mimic the action of a hormone called glucagon-like peptide 1, which stimulates insulin production and lowers blood sugar levels